IMV Inc.

and welcome to IMB's fourth quarter and fiscal 2021 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star then one on your touchstone telephone. If anyone should require assistance during the conference, please press star then zero to reach an operator. As a reminder, this call may be recorded. I would like to turn the call over to Joy Bessinger, Head of Investor Relations and Corporate Strategies. You may begin. Thank you, Michelle.

Good morning, everyone. I'm Joy Bessinger, Head of Investor Relations and Corporate Strategy for IMB, and I'm pleased to welcome you to our fourth quarter clinical and operational update conference call. I'm joined today by Andrew Hall, our CEO, Dr. Jeremy Graff, our CSO, and Pierre LeBay, our CFO. During this call, we will discuss our business outlook and make forward-looking statements. Any forward-looking statements made today are pursuant to and within the meaning of the safe harbor provisions of applicable securities laws. These comments are based on current expectations of management regarding future events and operating performance and should not be seen as guarantees of future performance or results. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks are discussed in our continuous disclosure documents filed in compliance with the applicable securities laws in Canada and the United States. The press release, the annual information forum, the MD&A, and the financial statements have all been posted on our website at imv-inc.com. If you wish to receive a copy of these documents, please contact us. Please note, as always, that we will take questions from sell-side analysts only, and I now turn the call over to Andrew to provide an overview of our recent highlights and to set the stage for what to expect in 2022. Andrew?

Thank you, Joy, and good morning, everyone. Welcome to IMB's clinical, operational, and fourth quarter and year-end results call. I'll provide a brief overview of our recent milestones and a look ahead to what 2022 will look like for IMB. Jeremy will then discuss recent highlights of our clinical, translational and foundational programs, including some key points from our recent R&D day. And finally, Pierre will provide an overview of our financial results for the fourth quarter and year end 2021 before we take questions. In 2022, importantly, we advanced MVPS closer towards registration with the initiation of a Phase IIb clinical study in DLBCL that we call Vitalise. We also completed the Phase II DECIDE-1 ovarian cancer trial and closed the basket trial highlighting the encouraging results in bladder cancer. We took action to extend our cash runway into the spring of 2023 and we reinforced the scientific foundations with presentations about technology, translational research and clinical data at various key scientific congresses. In a difficult year, these accomplishments have set the stage for a very important 2022. In 2022, we are continuing the expansion of our clinical programs with Maverick Peppermint as both a monotherapy and in combination with Keytruda across various settings in various different indications. MVPS has now shown definitive clinical benefit across multiple cancers in addition to a very attractive safety profile and an impressive durability of response. Coupled with supporting translational data, we believe that we're on the right path towards potential registration. This is a clear priority for IMV. As we make good progress with MVPS in the clinic, we are actively seeking opportunities to add depth to our pipeline by leveraging the versatility and novel mechanism of our DPX platform through business development. NVPS is an exemplar of what our platform can do. This is a repeatable plug-and-play model that we plan to capitalize on this year in parallel with our continued clinical progress. We anticipate that this will enable us to build a comprehensive pipeline of immune-educating programs that are improved by formulation with DPX. We remain open to out-licensing opportunities for our non-caller infectious disease programs. However, as we laid out in our quarter three call last year, we will not develop these programs in-house on our own. Our foundational research continues to further strengthen our approach and our platform. We are committed to presenting new data on both the mechanism of action and our clinical programs of high-profile scientific congresses and in peer-reviewed journals and clearly communicating our progress and milestones to all stakeholders. Our recent R&D Day event and upcoming late-breaking presentation at a plenary session at AACR are two examples of these efforts. In 2022, we will drive value through two strategic priorities. One, to accelerate Maverick Peppermint towards registration, and two, to further enrich our scientific foundation of the DPX platform to enable business development. I'll now pass to Jeremy to present the details of our recent clinical, translational and foundational science progress, as well as our upcoming 2022 milestones. Jeremy?